SG11201705767PA - Agent for preventing and/or treating amyotrophic lateral sclerosis - Google Patents

Agent for preventing and/or treating amyotrophic lateral sclerosis

Info

Publication number
SG11201705767PA
SG11201705767PA SG11201705767PA SG11201705767PA SG11201705767PA SG 11201705767P A SG11201705767P A SG 11201705767PA SG 11201705767P A SG11201705767P A SG 11201705767PA SG 11201705767P A SG11201705767P A SG 11201705767PA SG 11201705767P A SG11201705767P A SG 11201705767PA
Authority
SG
Singapore
Prior art keywords
preventing
agent
lateral sclerosis
amyotrophic lateral
treating amyotrophic
Prior art date
Application number
SG11201705767PA
Other languages
English (en)
Inventor
Haruhisa Inoue
Keiko Imamura
Original Assignee
Univ Kyoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kyoto filed Critical Univ Kyoto
Publication of SG11201705767PA publication Critical patent/SG11201705767PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201705767PA 2015-01-13 2016-01-13 Agent for preventing and/or treating amyotrophic lateral sclerosis SG11201705767PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015004589 2015-01-13
JP2015137909 2015-07-09
PCT/JP2016/050883 WO2016114322A1 (ja) 2015-01-13 2016-01-13 筋萎縮性側索硬化症の予防及び／又は治療剤

Publications (1)

Publication Number Publication Date
SG11201705767PA true SG11201705767PA (en) 2017-08-30

Family

ID=56405863

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201705767PA SG11201705767PA (en) 2015-01-13 2016-01-13 Agent for preventing and/or treating amyotrophic lateral sclerosis

Country Status (6)

Country Link
US (1) US20180000771A1 (ja)
EP (2) EP3789027A1 (ja)
JP (1) JP6852848B2 (ja)
CN (2) CN107530430A (ja)
SG (1) SG11201705767PA (ja)
WO (1) WO2016114322A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201714316D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatement of neurodegenerative diseases
US20200368267A1 (en) * 2017-11-24 2020-11-26 Kyoto University Prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis
CA3089630A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
EP3837011A4 (en) 2018-08-13 2022-05-18 The Regents Of The University Of Michigan METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS
CA3117020A1 (en) * 2018-10-19 2020-04-23 Aclipse One Inc. Treatment of neurological diseases
WO2020118282A1 (en) * 2018-12-07 2020-06-11 The Johns Hopkins University Methods, compositions and kits for treating multiple sclerosis and other disorders
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
JPWO2021075476A1 (ja) 2019-10-18 2021-04-22
KR20220123058A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물
DK4084778T3 (da) 2019-12-30 2023-12-11 Deciphera Pharmaceuticals Llc Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf
CA3172328A1 (en) * 2020-03-27 2021-09-30 Haruhisa Inoue Nerve cell degeneration inhibitor
WO2023212411A1 (en) * 2022-04-29 2023-11-02 Indiana University Research And Technology Corporation Methods of treating neuropathy using foretinib and compositions thereof
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2024187126A1 (en) * 2023-03-09 2024-09-12 Aquinnah Pharmaceuticals, Inc. Inhibitors of tdp-43 and tau aggregation

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
FR2688138B1 (fr) 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
ME00415B (me) 2000-02-15 2011-10-10 Pharmacia & Upjohn Co Llc Pirol supstituisani 2-indol protein kinazni inhibitori
MXPA03005696A (es) 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
PL209822B1 (pl) 2001-04-27 2011-10-31 Kirin Pharma Kk Pochodna chinoliny lub chinazoliny, zawierająca ją kompozycja farmaceutyczna i zastosowanie
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
WO2003092693A1 (en) * 2002-05-06 2003-11-13 Washington University Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
MXPA05009063A (es) 2003-02-26 2005-12-12 Sugen Inc Compuestos de aminoheteroarilo como inhibidores de proteina cinasa.
JPWO2004091663A1 (ja) * 2003-04-18 2006-07-06 協和醗酵工業株式会社 神経再生薬
RU2006113691A (ru) 2003-11-06 2007-12-20 Вайет (Us) Применение 4-анилин-3-хинолинкарбонитрилов для лечения хронической миелогенной лейкемии (cml)
NZ554009A (en) * 2004-10-18 2010-09-30 Medvet Science Pty Ltd Use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor C-FMS
US20090143433A1 (en) * 2004-12-01 2009-06-04 Curt Hendrix Cocktail for modulation of alzheimer's disease
WO2008031835A2 (en) * 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors
GB2458259A (en) * 2008-02-05 2009-09-16 Univ Aberdeen Neuroprotective 3-phenylacrylonitrile (3-PAN) derivatives
WO2010017541A2 (en) * 2008-08-08 2010-02-11 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
US9265764B2 (en) * 2009-02-27 2016-02-23 Massachusetts Institute Of Technology Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
US20110129463A1 (en) * 2009-11-27 2011-06-02 Proteologics, Ltd. Quinazolin-4(3A)-One Derivatives and Methods of Use Thereof
EP2512514B1 (en) 2009-12-14 2014-11-05 Kyoto University Screening method for identifying compounds for treating amyotrophic lateral sclerosis
US9856210B2 (en) * 2010-09-02 2018-01-02 Kyoto University Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
WO2012048330A2 (en) * 2010-10-08 2012-04-12 The Mclean Hospital Corporation Treatment of motor neuron disease
JP6023082B2 (ja) * 2011-01-24 2016-11-09 インセプタム リサーチ アンド セラピューティクス，インク． 精神神経性の疾病を処置するためのプロスタグランジンを含む組成物
EP2804598B1 (en) 2012-01-17 2019-05-15 Kyoto University Prophylactic and therapeutic drug for amyotrophic lateral sclerosis and method of screening therefor
EP2626073A1 (en) * 2012-02-13 2013-08-14 Harmonic Pharma Compound for use in the prevention and/or treatment of a neurogenerative disease or a disease involving an activation of phosphodiesterase-4 (PDE4)
EP2844256B1 (en) * 2012-05-02 2023-02-22 Georgetown University Treating amyotrophic lateral sclerosis with tyrosine kinase inhibitors
CA2868958C (en) * 2012-05-15 2020-09-01 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
WO2013177367A2 (en) * 2012-05-23 2013-11-28 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
CN104520291A (zh) * 2012-06-06 2015-04-15 Irm责任有限公司 用于调节egfr活性的化合物和组合物
JP6473077B2 (ja) 2013-03-21 2019-02-20 国立大学法人京都大学 神経分化誘導用の多能性幹細胞
US20160082015A1 (en) * 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
JP6138602B2 (ja) 2013-06-21 2017-05-31 前田建設工業株式会社 孔壁内面形状の計測装置
JP2015137909A (ja) 2014-01-22 2015-07-30 株式会社島津製作所 エッチングモニタ装置

Also Published As

Publication number Publication date
US20180000771A1 (en) 2018-01-04
CN107530430A (zh) 2018-01-02
CN113181362A (zh) 2021-07-30
EP3246046A1 (en) 2017-11-22
WO2016114322A1 (ja) 2016-07-21
JPWO2016114322A1 (ja) 2017-10-19
EP3789027A1 (en) 2021-03-10
EP3246046A4 (en) 2018-12-05
JP6852848B2 (ja) 2021-03-31
CN113181362B (zh) 2023-06-13

Similar Documents

Publication Publication Date Title
SG11201705767PA (en) Agent for preventing and/or treating amyotrophic lateral sclerosis
IL278001B (en) Preparations and methods for the treatment of amyotrophic lateral sclerosis
EP3119797A4 (en) Raav-based compositions and methods for treating amyotrophic lateral sclerosis
IL257587B (en) Compounds for treating amyotrophic lateral sclerosis
PL3668509T3 (pl) Sposób leczenia stwardnienia zanikowego bocznego pridopidiną
SG11201803669UA (en) Microorganism-controlling agent and miticidal composition
ZA201907975B (en) Agent for preventing or treating tauopathy
ZA201907973B (en) Agent for preventing or treating brain atrophy
IL291266A (en) Preparations and methods for treating infections
IL283833A (en) Preparations and methods for the treatment and prevention of lateral column sclerosis in the spine
PL3129378T3 (pl) Związki hamujące bromodomenę i zawierająca je kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu
EP3290053A4 (en) EXTERNAL AGENT FOR THE TREATMENT OF HYPERHIDROSIS
IL254619A0 (en) Biotin for the treatment of lateral column sclerosis in the spine
PT3290051T (pt) Composição farmacêutica para o tratamento e/ou prevenção de cancro
IL260331A (en) Compounds and methods for the treatment of amyotrophic lateral sclerosis
PL3658174T3 (pl) Laktoferycyna i laktoferampina do leczenia infekcji
ZA201802268B (en) Methods and compositions for preventing or treating cancer
HK1249035A1 (zh) 降低成像後胰腺炎風險的組合物和方法
IL261360A (en) Compound and method for treating amyotrophic lateral sclerosis
HUE066272T2 (hu) Terápiás szer az amiotrófiás laterálszklerózisra és a kezelésre szolgáló készítmény
IL257407A (en) Compositions and methods for treating wounds
GB2558090B (en) Prevention and treatment for microbial infections
EP3648768C0 (fr) Iméglimine pour la prévention et/ou le traitement du carcinome hépatocellulaire
SG11201804140PA (en) Acidic-gas treating agent and acidic-gas treating method
GB201518489D0 (en) Methods for the treatment and prevention of ebola